Santhera Pharmaceuticals has announced positive findings from the LIONHEART study, confirming vamorolone’s unique role as a mineralocorticoid receptor antagonist

Enliven Therapeutics, a clinical-stage biopharmaceutical company, announced updated positive results from the phase 1 trial of ELVN-001 in chronic myeloid leukemia (CML

Medtronic plc, a global leader in healthcare technology, has announced clinical results showing high rates of durable lesion formation using the PulseSelect Pulsed Fiel

Medtronic has released preliminary findings from its study on the adaptive deep brain stimulation (aDBS) device, Percept PC neurostimulator, aimed at patients with Park

Roche announced positive topline results from the Phase III CENTERSTONE trial of Xofluza (baloxavir marboxil), an antiviral for influenza. This single-dose oral treatme

Boehringer Ingelheim announced that the FIBRONEER-IPF trial successfully met its primary endpoint, demonstrating a significant change in Forced Vital Capacity (FVC) at

Roche has announced positive topline results from the phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an antiviral drug that significantly reduces the tran

Initial results from the phase 1 trial of DS-9606 indicate promising clinical activity in patients with advanced solid tumors expressing Claudin-6 (CLDN6). Presented at

Tectonic Therapeutic has reported positive topline results from its Phase Ia trial of TX45, a treatment for Group 2 pulmonary hypertension-heart failure with preserved

Aligos Therapeutics has reported promising topline results from its Phase IIa HERALD clinical trial of ALG-055009, a thyroid hormone receptor beta agonist, aimed at tre

Aura Biosciences, Inc., a biotechnology company focused on precision therapies for solid tumors, announced positive results from its Phase 2 trial evaluating bel-sar (A

VYNE Therapeutics Inc. announced promising results from the single ascending dose (SAD) phase of its phase 1a trial for VYN202, an innovative oral BET inhibitor. This t

Bayer recently presented detailed findings from the OASIS 3 phase III study at the 2024 annual meeting of The Menopause Society (TMS) in Chicago. The study demonstrated

Acelyrin, Inc., a late-stage clinical biopharmaceutical company, announced encouraging results from its global phase 3 clinical trial of izokibep for patients with mode

Relay Therapeutics, Inc., a clinical-stage precision medicine company, shared promising interim data for RLY-2608, the first investigational allosteric, pan-mutant, and

GSK plc announced positive results from a Phase II trial (NCT06431607) for its mRNA seasonal influenza vaccine program. The trial evaluated different mRNA formulations

Merck (known as MSD outside the U.S. and Canada) reported positive top-line results from a Phase 3 trial (V503-064) evaluating Gardasil 9, a 9-valent HPV vaccine, in Ja

Boehringer Ingelheim and CDR-Life have announced positive results from the Phase I trial of BI 771716, a new treatment for geographic atrophy (GA), a severe form of lat

Eli Lilly and Company has announced promising results from Phase III trials of once-weekly insulin efsitora alfa (efsitora) for treating type 2 diabetes (T2D). The QWIN

Vesper Bio has shared results from a Phase I study of VES001, a potential disease-modifying treatment for frontotemporal dementia (FTD) targeting patients with progranu

Biogen's higher dose of Spinraza (nusinersen) for spinal muscular atrophy (SMA) has met the primary endpoint in a Phase II/III DEVOTE study. The trial showed that infan

Roche will present new 48-week data from the phase II FENopta open-label extension (OLE) study of fenebrutinib at the ECTRIMS Congress in Copenhagen on September 18, 20

Valneva SE and Pfizer Inc. reported positive results from their VLA15-221 Phase 2 study of the Lyme disease vaccine candidate, VLA15. This study assessed the safety and

RegenxBio has announced positive long-term results from its pivotal study of RGX-121 for mucopolysaccharidosis type II (MPS II). The September 3 press release revealed

Arrowhead Pharmaceuticals is preparing to file a New Drug Application (NDA) to the FDA following the release of full data from a key Phase III trial of its lead dr

Valneva and Pfizer have announced positive results from the Phase II VLA15-221 trial, which tested a second booster dose of their Lyme disease vaccine candidate, VLA15,

The Phase III FINEARTS-HF study revealed that finerenone (Kerendia/Firialta) significantly improved cardiovascular outcomes in heart failure (HF) patients with a left v

Positive results from the HERCULES Phase 3 study showed that tolebrutinib, Sanofi’s oral brain-penetrant BTK inhibitor, significantly delayed disability progressi

An AI tool developed by Ultromics showed lower accuracy compared to traditional clinical decision-making when identifying patients for further follow-ups, although it m

Merck & Co (MSD) has discontinued two Phase III Keytruda (pembrolizumab) trials. The KEYNOTE-867 trial, testing Keytruda with stereotactic body radiation therapy (S

Neurocrine Biosciences has reported positive results from its Phase II study of NBI-1117568, an oral schizophrenia treatment. The trial, NBI-‘568-SCZ2028, achieve

Novartis has announced that its Phase III V-MONO trial of Leqvio (inclisiran), an siRNA therapy, met its primary endpoints. The six-month, randomized, double-blind tria

Aadi Biosciences is implementing cost-saving measures after halting its registrational Phase II PRECISION1 trial for the mTOR inhibitor nab-sirolimus. The Independent D

Jazz Pharmaceuticals faced a setback in Japan as a Phase III trial for its cannabidiol therapy did not meet its primary endpoint. The study aimed to assess the oral can

Innovo Therapeutics has reported positive results from its Phase II clinical trial of INV-001, a treatment for reducing post-thyroidectomy scars. Conducted at four hosp

A year after investing in Timber Pharmaceuticals' pipeline, Leo Pharma has reported a Phase III failure for TMB-001, a topical isotretinoin ointment. The ASCEND trial (

Israel-based specialty pharmaceutical company PainReform has announced positive initial safety results from its Phase III bunionectomy trial of PRF-110, a post-surgical

Sobi and Apellis Pharmaceuticals have released positive results from the Phase III VALIANT trial, evaluating pegcetacoplan for C3 glomerulopathy (C3G) and primary immun

AN2 Therapeutics has implemented cost-cutting measures following disappointing Phase II results from its Phase II/III trial of epetraborole, its lead antibiotic. The co

Following a recent trial failure, the future of Ultimovacs’ UV1 cancer vaccine now hinges on the Phase II DOVACC trial, with results expected in the first half of

Reproxalap has demonstrated enhanced efficacy in alleviating symptoms of dry eye disease and reducing ocular redness. Aldeyra Therapeutics has achieved the primary endp

AstraZeneca's Phase III AMPLIFY trial has reported positive results for Calquence (acalabrutinib) in treating chronic lymphocytic leukemia (CLL). This global, open-labe

Longeveron has reported that the Phase IIa CLEAR MIND trial of Lomecel-B for mild Alzheimer’s disease successfully met its primary safety and secondary efficacy e

Natera has revealed data on its MRD test, Signatera, for detecting Merkel cell carcinoma, an aggressive skin cancer. Published in the Journal of Clinical Oncology, the

Vaccinex, Inc. announced positive early results from its SIGNAL-AD trial of pepinemab for Alzheimer’s disease (AD). Presented by Eric Siemers, MD, at the Alzheime

Magnus Medical's study on its neuromodulation system, SAINT, showed positive results in treating treatment-resistant depression with sustained clinical benefits for up

Eli Lilly has announced positive results from the Phase III SUMMIT trial of tirzepatide in adults with heart failure with preserved ejection fraction (HFpEF) and obesit

PepGen has announced positive results from the first dose cohort (5mg/kg) of its CONNECT1-EDO51 Phase II trial for PGN-EDO51, an investigational therapy for Duchenne mu

Bayer’s phase III FINEARTS-HF study has met its primary endpoint, demonstrating that finerenone significantly reduces cardiovascular death and heart failure (HF)

Ultimovacs' UV1 cancer vaccine, combined with MSD’s Keytruda (pembrolizumab), failed to meet primary and secondary endpoints in the Phase II FOCUS trial (NCT05075

Pfizer Inc. reported positive results from the Phase 3 AFFINE study (NCT04370054) of giroctocogene fitelparvovec, a gene therapy for adults with moderately severe to se

Cytoki Pharma, ApS reported positive Phase 1 results for CK-0045, a lipidated IL-22 candidate, in healthy participants and those with obesity. The study evaluated CK-00

Merck (MSD outside the US and Canada) announced positive topline results from its phase 2b/3 trial (MK-1654-004) of clesrovimab (MK-1654), an investigational monoclonal

GSK plc's ViiV Healthcare released 48-week results from the PASO DOBLE Phase IV trial, comparing Dovato (dolutegravir/lamivudine [DTG/3TC]) to Biktarvy (bictegravir/emt

Ionis Pharmaceuticals, Inc. reported positive results from the completed multiple ascending dose (MAD) phase 1/2 open-label study of ION582 in Angelman syndrome (AS) pa

GSK plc's ViiV Healthcare released 48-week results from the PASO DOBLE Phase IV trial, comparing Dovato (dolutegravir/lamivudine [DTG/3TC]) to Biktarvy (bictegravir/emt

Roche has unveiled four-year data from the RHONE-X extension study, revealing that Vabysmo (faricimab) was well-tolerated in diabetic macular edema (DME) patients. The

The phase III ARANOTE trial found that darolutamide plus androgen deprivation therapy (ADT) significantly improved radiological progression-free survival (rPFS) in meta

Roche has announced positive results from two arms of the ongoing phase I ARANOTE trial for CT-996, an investigational, once-daily oral GLP-1 receptor agonist for treat

Azafaros has announced positive results from the Phase II RAINBOW trial of nizubaglustat for treating GM2 gangliosidosis and Niemann-Pick disease type C (NPC). Conducte

Roche has reported positive topline results from the Phase I CT-996-201 trial of CT-996, an oral GLP-1 receptor agonist for type 2 diabetes (T2D) and obesity. This tria

Roche has released four-year results from the RHONE-X extension study, which assessed the long-term safety and efficacy of Vabysmo (faricimab) for diabetic macular edem

AVEO Oncology has reported mixed results from its recent trials. The Phase III TiNivo-2 trial (NCT04987203) did not achieve its primary endpoint of progression-free sur

Teva Pharmaceutical has announced positive results from the Phase III SPACE trial of AJOVY (fremanezumab) for preventing episodic migraines in children and adolescents

Alkeus Pharmaceuticals has reported interim data from the TEASE-3 trial showing that gildeuretinol acetate effectively halts early-stage Stargardt disease progression.<

AB Science has reported positive results from its Phase II trial of masitinib in hospitalized Covid-19 patients, combined with isoquercetin. The treatment improved pati

Ideaya Biosciences, a US biotech firm, has released promising interim results from a Phase II trial of IDE397 for treating methylthioadenosine phosphorylase (MTAP) dele

Guangzhou Zhiyi Biotechnology (Zhiyi Biotech) has released promising findings from its Phase I clinical trial conducted in the US on SK10, a heat-killed form of Bactero

Navidea Biopharma has dropped its rheumatoid arthritis (RA) program following disappointing results from the NAV3-33 trial's exploratory analysis. The Phase III study (

Know Labs, based in the US, has released promising findings from a proof-of-concept trial evaluating its non-invasive device designed to detect blood sugar levels in di

UniQure's stock price has surged over 100% following positive interim results from Phase I/II trials of its gene therapy for Huntington’s disease. In the high-dos

Johnson & Johnson reported positive results from the phase 3 CARTITUDE-4 study's second interim analysis, comparing Carvykti (ciltacabtagene autoleucel; cilta-cel)

Alvotech has reported positive topline data from the AVT03-GL-C01 study, evaluating AVT03 as a biosimilar to denosumab drugs Prolia and Xgeva. This randomized, double-b

Mendel, a clinical AI firm, has announced results from a trial showing its Neuro-Symbolic system outperforms current models like GPT-4 in sorting patient cohorts from e

Cartesian Therapeutics has declared positive results from its Phase IIb trial of Descartes-08, an autologous mRNA-engineered CAR-T therapy, in generalized myasthenia gr

TRACON Pharmaceuticals has discontinued its Phase II ENVASARC trial for envafolimab, a sarcoma therapy, due to inadequate efficacy findings that cannot support a biolog

Roche's phase II/III SKYSCRAPER-06 study evaluating tiragolumab with Tecentriq (atezolizumab) and chemotherapy as a first-line treatment for untreated non-squamous non-

Noah Medical, based in the US, has published promising results from a clinical study on its Galaxy surgical robotic system in the Asian Pacific Society of Respirology j

Cartesian Therapeutics has reported promising findings from its Phase IIb trial evaluating Descartes-08, an autologous mRNA-engineered CAR-T cell therapy, in generalize

Alvotech has announced positive top-line results from its confirmatory patient study, AVT03-GL-C01, evaluating AVT03 as a proposed biosimilar to denosumab drugs Prolia

Johnson & Johnson (J&J) has announced positive results from the second interim analysis of the Phase III CARTITUDE-4 trial evaluating CARVYKTI (ciltacabtagene a

INmune Bio’s AD02 trial has successfully resumed following a previous FDA clinical hold, focusing on its primary endpoint, the Early Mild Alzheimer’s Cognit

Sanofi reported positive Phase III trial results for Dupixent (dupilumab) in children aged one to eleven years with eosinophilic esophagitis (EoE). This trial assessed

AstraZeneca, a UK-based pharmaceutical company, has reported outcomes from the ADJUVANT BR.31 Phase III trial of Imfinzi (durvalumab), indicating that the trial did not

Keymed Biosciences has released promising results from a Phase I/II study of CM313 in adults with primary immune thrombocytopenia (ITP). This investigator-initiated, si

Ethris, a German biotech company, has released promising Phase I data on its intranasal mRNA candidate, ETH47. The trial (ISRCTN15391202) showed ETH47 administered nasa

Vertex Pharmaceuticals presented new data from its phase 1/2 trial of VX-880, a stem cell-derived islet cell therapy, for type 1 diabetes (T1D) patients with severe hyp

Alnylam Pharmaceuticals saw its stock rise by 32% following positive results from the late-stage study of its RNA interference (RNAi) therapy, vutrisiran, for treating

Takeda has reported positive results from its Phase IIb trial of mezagitamab (TAK-079) for primary immune thrombocytopenia (ITP), a rare bleeding disorder. This double-

Alligator Bioscience shared positive results from its Phase Ib/II OPTIMIZE-1 trial (NCT04888312) for mitazalimab, a monoclonal antibody therapy targeting pancreatic can

4DMT is advancing to Phase II of its AEROW trial following encouraging interim results for gene therapy 4D710 in cystic fibrosis (CF). Combining an AAV vector with a CF

Advanced BioDesign has disclosed initial findings from its ODYSSEY trial, examining ABD-3001 (Sefaldin) efficacy in treating refractory acute myeloid leukemia (AML). AB

Amgen shared positive results from its phase 3 trial (NCT04540497) on Uplizna (inebilizumab-cdon) for treating immunoglobulin G4-related disease (IgG4-RD).

Takeda and Pfizer have jointly announced positive outcomes from the Phase III HD21 trial, assessing ADCETRIS (brentuximab vedotin) combined with chemotherapy.

AbbVie announced positive results from the Phase II PICCOLO trial of mirvetuximab soravtansine (ELAHERE) monotherapy in heavily pre-treated high folate receptor-alpha (

Johnson & Johnson (J&J) has reported positive results from its Phase III trial of seltorexant in major depressive disorder (MDD), meeting all primary and second

Gilead Sciences, Inc. released findings from the phase 3 TROPiCS-04 study in metastatic urothelial cancer (mUC), comparing Trodelvy (SG) to chemotherapy in patients who

Innovent Biologics, Inc., a renowned biopharmaceutical firm focusing on cancer, metabolic, autoimmune, and other diseases, has revealed the success of its phase 3 study

Xeris Biopharma Holdings, Inc., a biopharmaceutical company dedicated to advancing patient care, has unveiled promising results from its phase 2 trial of XP-8121 for tr

Ultragenyx Pharmaceutical Inc., dedicated to addressing rare genetic diseases, reported positive findings from its phase 3 GlucoGene study (NCT05139316) evaluating DTX4

Amgen and AstraZeneca released results from the phase 2a COURSE trial assessing Tezspire (tezepelumab-ekko) in individuals with moderate to very severe chronic obstruct

Merus's bispecific antibody petosemtamab targets both epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5). Am

Vicore Pharma Holding AB unveiled positive final results from its phase 2a AIR trial evaluating buloxibutid (C21) in idiopathic pulmonary fibrosis (IPF) at the American

Medtronic plc, a global healthcare technology leader, announced promising results from the SPHERE Per-AF study, evaluating the Affera Mapping and Ablation System with S

GSK plc reported positive outcomes from phase III trials SWIFT-1 and SWIFT-2, evaluating depemokimab's efficacy and safety in severe asthma with type 2 inflammation. Bo

Nimbus Therapeutics has released encouraging results from its Phase I/II clinical trial of NDI-101150, an oral small-molecule inhibitor targeting hematopoietic progenit

SPR Therapeutics announced positive results from a study evaluating its peripheral nerve stimulation (PNS) device for alleviating chronic knee pain post knee replacemen

Vanda Pharmaceuticals announced positive results from its Phase III trial of tradipitant for motion sickness, named Motion Serifos. The trial involved 316 participants

 Novo Nordisk has shared headline results from FRONTIER II, a Phase IIIa trial assessing subcutaneous Mim8 for haemophilia A treatment.

18-05-2024

AstraZeneca’s Phase III Covid-19 antibody trial meets primary endpoints

Roche anticipates benefiting from the obesity therapy market following positive Phase Ib trial results for its investigational obesity and type 2 diabetes treatment, CT

Boehringer Ingelheim released positive findings from the HORNBILL Phase I/IIa trial assessing BI 764524, a humanized monoclonal anti-Sema3A antibody, for diabetic macul

Teva and Medincell have disclosed positive outcomes from the Phase III Subcutaneous OLAnzapine Extended-Release Injection Study (SOLARIS), assessing TEV-‘749 (ola

AngioDynamics has unveiled data showing the safety and efficacy of its AlphaVac F1885 System in patients with acute intermediate-risk pulmonary embolism (PE), demonstra

Merck & Co (MSD) announced that its Phase III KEYNOTE-B21 trial, studying Keytruda with chemotherapy in newly diagnosed high-risk endometrial cancer post-surgery, d

AstraZeneca's Phase III ECHO trial showed promising results for Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, combined with standard chem

Leo Pharma has released promising findings from a Phase III clinical trial of Enstilar (LEO 90100) for Chinese adult patients with stable plaque psoriasis. Enstilar, an

Micron Medical's Phase I/II trial, detailed in The Lancet, underscores the safety and efficacy of its measles and rubella microneedle patch (MNP), offering a needle-fre

Micron Medical's Phase I/II trial, detailed in The Lancet, underscores the safety and efficacy of its measles and rubella microneedle patch (MNP), offering a needle-free vaccination option. Results

Newron Pharmaceuticals' evenamide study has achieved its primary endpoint, demonstrating improvement in positive and negative symptoms, and severity in patients with tr

Biological E. Limited (BE), based in Hyderabad, disclosed phase-III trial results for its 14-Valent Pneumococcal Conjugate Vaccine (PCV), Pneubevax 14 (BE-PCV-14), in V

Merck, known as MSD outside the US and Canada, announced that its phase 3 trial KEYNOTE-811 evaluating Keytruda (pembrolizumab) with trastuzumab and chemotherapy met it

Neurocrine Biosciences reports positive findings from the Phase II SAVITRI trial of NBI-1065845 for major depressive disorder (MDD) in adults.

30-04-2024

Kintor Pharma’s GT20029 Phase II trial meets primary endpoint

Addex Therapeutics, a clinical-stage biopharmaceutical company, disclosed phase 2 epilepsy study results for adjunctive ADX71149 (JNJ-40411813) in patients with inadequ

The DESTINY-Breast06 phase III trial unveiled positive outcomes, showing Enhertu's (trastuzumab deruxtecan) significant progression-free survival (PFS) improvement

German pharmaceutical company Merck KGaA (Merck) has reported positive results from its Phase III STRIDE-10 trial of V116, a pneumococcal conjugate vaccine aimed at pre

Alto Neuroscience has reported positive results from its Phase I trial of ALTO-101, a PDE4 inhibitor for treating cognitive impairment in schizophrenia (CIAS). The stud

In February, Gain Therapeutics revealed preclinical data indicating that GT-02287 restored motor function and significantly reduced plasma neurofilament light chain (Nf

Joincare Pharmaceutical, based in China, has achieved the primary endpoint in a Phase III trial for its flu candidate TG-1000, in collaboration with Taiwan's TaiGen Bio

GSK has reported favorable outcomes from the Phase III EAGLE-1 clinical trial of gepotidacin, an oral bactericidal triazaacenaphthylene antibiotic, in treating uncompli

Marinus Pharmaceuticals announced that its Phase III RAISE study (NCT04391569) of IV ganaxolone for status epilepticus (SE) didn't meet early stopping criteria. They pl

Barinthus Biotherapeutics (formerly Vaccitech) released topline data from its Phase Ib/II APOLLO trial for HPV treatment, VTP-200. The randomized APOLLO trial (NCT04607

Cerevel Therapeutics released positive Phase III TEMPO-3 trial results for tavapadon in Parkinson's disease. Tavapadon, a D1/D5 receptor partial agonist, showed efficac

US-based biopharmaceutical company Acadia Pharmaceuticals has announced that its Phase III ADVANCE-2 clinical trial evaluating pimavanserin for the treatment of negativ

Enlivex Therapeutics has disclosed promising top-line results regarding safety and efficacy from its Phase II clinical trial evaluating Allocetra, an off-the-shelf cell

Teva Pharmaceuticals has released encouraging results from a Phase III trial assessing Ajovy (fremanezumab) for migraine prevention in Chinese adult patients.

Amyyx Pharmaceuticals has released promising interim results from its Phase II trial of Relyvrio (AMX0035) for Wolfram syndrome, a rare disease.

13-04-2024

NeuroGenesis declares positive data from multiple sclerosis trial

The ADRIATIC phase III trial unveiled promising results indicating AstraZeneca’s Imfinzi (durvalumab) significantly enhanced overall survival (OS) and progression

Viking Therapeutics has reported positive data from its Phase I multiple ascending dose (MAD) clinical trial of VK2735, an oral tablet under investigation for treating

Bristol Myers Squibb (BMS) disclosed positive results from its Phase III KRYSTAL-12 trial of KRAZATI (adagrasib) for treating non-small cell lung cancer (NSCLC) with KR

Moderna has disclosed promising interim findings from the Phase III NextCOVE clinical trial, demonstrating the efficacy of its next-generation COVID-19 vaccine candidat

LENZ Therapeutics disclosed positive results from the Phase III CLARITY study assessing aceclidine formulations, LNZ100 and LNZ101, for presbyopia treatment.

HealthNet Global (HNG) introduces its Tele-ICU program at the inauguration of Apollo Spectra Hospital in Pusa Road, Delhi, marking a significant advancement in critical

Pfizer Inc. has announced positive results from a phase 3 trial of Adcetris (brentuximab vedotin) in combination with lenalidomide and rituximab for relapsed/refractory

CuraTeQ Biologics Private Limited, a subsidiary of Aurobindo Pharma Ltd, announced that their omalizumab biosimilar candidate BP11 met phase 1 trial endpoints compared

OcuTerra Therapeutics reported that its Phase II DREAM trial of nesvategrast (OTT166) eye drops for diabetic retinopathy (DR) didn't meet endpoints. The study aimed to

Bristol Myers Squibb has announced positive findings from the phase 3 CheckMate -9DW trial, evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as first-line therapy

Nuvectis Pharma, Inc., a biopharmaceutical company, shared positive preliminary findings from a phase 1b trial of NXP800 for platinum-resistant ARID1a-mutated ovarian c

Ionis Pharmaceuticals, Inc. has released positive outcomes from a phase 2 trial of ION224, an investigational DGAT2 antisense inhibitor targeting metabolic dysfunction-

GSK plc announced positive interim results from the DREAMM-8 phase III trial, comparing Blenrep (belantamab mafodotin) plus pomalidomide and dexamethasone (PomDex) agai

Roche and Alnylam reported positive results from the phase II KARDIA-2 trial [NCT05103332] of zilebesiran, an investigational RNAi therapy for hypertension, a primary c

Bayer AG and BlueRock Therapeutics LP, an independently operated subsidiary of Bayer AG, have disclosed 18-month data from a phase I clinical trial on bemdaneprocel, an

MAIA Biotechnology has released positive efficacy results from its Phase II THIO-101 trial, examining THIO combined with cemiplimab (Libtayo) for advanced non-small cel

Viking Therapeutics, Inc. (Viking), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder treatments, reported positive outcomes f

GSK plc announced positive outcomes from the pivotal EAGLE-1 phase III trial of gepotidacin, an oral antibiotic targeting urogenital gonorrhea in adults and adolescents

Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, shares an R&D update. Positive top-line results from a recent phase 1 trial of MTX110 in di

Bristol Myers Squibb revealed findings from the phase 3 DAYBREAK trial, demonstrating Zeposia's (ozanimod) enduring efficacy and safety in relapsing forms of multiple s

Cynata Therapeutics Limited, a biotech firm specializing in cell therapeutics, completed the initial analysis of wound surface area in the first 16 patients of its phas

Novartis revealed new data affirming the clinical advantages of Zolgensma (onasemnogene abeparvovec), the sole one-time gene therapy for spinal muscular atrophy (SMA).<

Ultimovacs, a biotechnology company in its clinical stages, has unveiled data from the Phase II NIPU trial on the UV1 cancer vaccine, focusing on mesothelioma. This tri

Pfizer's Phase III RENOIR trial reveals top-line data on its respiratory syncytial virus (RSV) vaccine, ABRYSVO, targeting RSV-related lower respiratory tract disease (

GSK plc and ViiV Healthcare, a specialized HIV company majority-owned by GSK with Pfizer and Shionogi as shareholders, announced positive phase I study results for cabo

CASI Pharmaceuticals and BioInvent International unveiled positive initial efficacy findings from their Phase I trial of BI-1206 in relapsed/refractory indolent non-Hod

Sanofi, a French pharmaceutical company, is developing frexalimab under an exclusive license from ImmuNext. Positive Phase II trial results were recently announced for

HMB-001 is assessed as a prophylactic treatment for a bleeding disorder, Glanzmann thrombasthenia. Hemab Therapeutics has unveiled encouraging preliminary data from the

The antibody IBI311 showed favorable safety in Thyroid Eye Disease (TED) patients. Innovent Biologics disclosed positive results from the Phase III RESTORE-1 trial in C

Stress urinary incontinence, marked by urine leakage during activities like exercise or sneezing, is the focus of UroMems' latest trial evaluating its UroActive device.

Symptoms of amyotrophic lateral sclerosis (ALS) include hand and arm motor control loss and limb usage impairment. NeuroSense released additional top-line data from its

The LAURA phase III trial highlights AstraZeneca's Tagrisso (osimertinib) as a promising intervention, demonstrating a statistically significant improvement in progress

Tharimmune, a US biotech firm, has unveiled promising data on TH104, a transmucosal buccal film designed for liver-related and inflammatory conditions. TH104 targets ai

Sanofi and Denali Therapeutics' ALS therapy, SAR443820/DNL788, didn't meet its primary endpoint in the Phase II HIMALAYA trial. The trial aimed to gauge its effect on t

Grifols, a leading producer of plasma-derived medicines, announced positive results from Biotest's phase 3 trial of fibrinogen concentrate (FC), BT524, for acquired fib

Grifols, a global leader in plasma-derived medicines, celebrates Biotest's phase 3 trial success with BT524, a fibrinogen concentrate (FC) for acquired fibrinogen defic

Beacon Therapeutics Holdings Limited, a leading ophthalmic gene therapy company, presented interim results from the phase 2 SKYLINE trial for X-linked retinitis pigment

Chugai Pharmaceutical Co., Ltd. announced that the anti-CD20/CD3 bispecific antibody mosunetuzumab met the primary endpoint of complete response rate (CRR) in a Japanes